Chad Messer

Chad Messer has over 20 years of experience in the biotechnology industry. Chad began their career in 2000 at Genaissance Pharmaceuticals, where they held various roles including Corporate Development. In 2005, they joined Paramount BioCapital LLC as the Associate Vice President of Business Development. In 2006, they became a Research Analyst- Biotechnology at Piper Jaffray, where they specialized in Oncology, Infectious disease, and Neuro/Psych. In 2012, they moved to Needham & Company as a Managing Director and Senior Research Analyst- Biotechnology. In 2021, they joined atai Life Sciences as the Vice President of Investor Relations and Strategic Finance. Most recently, in 2022, they became the Vice President of Investor Relations at Cullinan Oncology.

Chad Messer has a diverse educational background. Chad holds a PhD in Pharmacology from Yale University, an MBA in Business Administration and Management, General from New York University, a BS in Biology from Yale University, and a High School diploma from The Kent School. Additionally, they have obtained certifications from FINRA (Financial Industry Regulatory Authority) in Series 7, 24, 63, 86, and 87.